Universe Pharmaceuticals Inc Net Assets
Universe Pharmaceuticals Inc net assets. Based on the latest financial reports, Universe Pharmaceuticals Inc (UPC) has net assets worth $56.13 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($69.30 Million) and total liabilities ($13.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore UPC net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $56.13 Million |
| % of Total Assets | 80.99% |
| Annual Growth Rate | 28.54% |
| 5-Year Change | -4.76% |
| 10-Year Change | N/A |
| Growth Volatility | 64.49 |
Net Assets of Universe Pharmaceuticals Inc (2018–2025)
Net assets of Universe Pharmaceuticals Inc from 2018 to 2025. This chart illustrates how Universe Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. See UPC net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Universe Pharmaceuticals Inc (2018–2025)
The table below shows the annual net assets of Universe Pharmaceuticals Inc from 2018 to 2025. For live market cap and overall valuation, see how much is Universe Pharmaceuticals Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $56.13 Million | +23.35% |
| 2024-09-30 | $45.50 Million | +15.10% |
| 2023-09-30 | $39.53 Million | -14.88% |
| 2022-09-30 | $46.44 Million | -21.20% |
| 2021-09-30 | $58.93 Million | +183.30% |
| 2020-09-30 | $20.80 Million | +67.98% |
| 2019-09-30 | $12.38 Million | +27.91% |
| 2018-09-30 | $9.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Universe Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 588.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Universe Pharmaceuticals Inc Net Assets Breakdown (September 2025)
Universe Pharmaceuticals Inc net assets breakdown by equity component as of September 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.34 Million | 11.29% |
| Other Comprehensive Income | $626.01K | 1.12% |
| Other Components | $63.01 Million | 112.26% |
| Total Equity | $56.13 Million | 100.00% |
Universe Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Universe Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
$839.64K |
|
Carr's Group plc
LSE:CARR
|
$840.50K |
|
Blockchaink2 Corp
V:BITK
|
$846.53K |
|
Magnum Goldcorp Inc
V:MGI
|
$847.35K |
|
Kooth plc
LSE:KOO
|
$838.94K |
|
MAPSPEOPLE A/S DK-02
F:70R
|
$837.90K |
|
Real Messenger Corporation Ordinary Shares
NASDAQ:RMSG
|
$835.98K |
|
E2Gold Inc
V:ETU
|
$830.10K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Universe Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 45,502,941 to 56,129,510, a change of 10,626,569 (23.4%).
- Net loss of 3,672,055 reduced equity.
- New share issuances of 15,000,000 increased equity.
- Other comprehensive income increased equity by 626,013.
- Other factors decreased equity by 1,327,389.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.67 Million | -6.54% |
| Share Issuances | $15.00 Million | +26.72% |
| Other Comprehensive Income | $626.01K | +1.12% |
| Other Changes | $-1.33 Million | -2.36% |
| Total Change | $- | 23.35% |
Book Value vs Market Value Analysis
This analysis compares Universe Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-09-30 | $1659.79 | $1.49 | x |
| 2019-09-30 | $2123.10 | $1.49 | x |
| 2020-09-30 | $3566.42 | $1.49 | x |
| 2021-09-30 | $11178.75 | $1.49 | x |
| 2022-09-30 | $7841.01 | $1.49 | x |
| 2023-09-30 | $6674.44 | $1.49 | x |
| 2024-09-30 | $1154.63 | $1.49 | x |
| 2025-09-30 | $16138.44 | $1.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Universe Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20.56%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.23x
- Recent ROE (-6.54%) is below the historical average (16.87%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 78.53% | 26.66% | 1.02x | 2.90x | $6.63 Million |
| 2019 | 60.98% | 22.73% | 1.86x | 1.44x | $6.31 Million |
| 2020 | 36.33% | 24.62% | 1.07x | 1.38x | $5.48 Million |
| 2021 | 19.21% | 23.59% | 0.68x | 1.19x | $5.43 Million |
| 2022 | -18.81% | -21.76% | 0.67x | 1.28x | $-13.38 Million |
| 2023 | -15.59% | -19.08% | 0.61x | 1.35x | $-10.12 Million |
| 2024 | -19.18% | -37.90% | 0.34x | 1.49x | $-13.28 Million |
| 2025 | -6.54% | -20.56% | 0.26x | 1.23x | $-9.29 Million |
Industry Comparison
This section compares Universe Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $100,165,415
- Average return on equity (ROE) among peers: -25.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Universe Pharmaceuticals Inc (UPC) | $56.13 Million | 78.53% | 0.23x | $839.37K |
| Aurora Cannabis Inc (ACB) | $1.71 Million | -2.57% | 0.01x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $166.09 Million | -138.50% | 2.72x | $143.73 Million |
| Akanda Corp (AKAN) | $-11.99 Million | 0.00% | 0.00x | $562.47K |
| Akebia Ther (AKBA) | $131.00 Million | -46.35% | 0.09x | $189.26 Million |
| Alkermes Plc (ALKS) | $161.37 Million | -10.45% | 1.50x | $7.61 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $3.22 Billion |
| Amphastar P (AMPH) | $329.25 Million | 3.20% | 0.30x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $208.93 Million | -62.22% | 17.18x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-44.54 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $85.19 Million | 5.07% | 0.51x | $279.44 Million |
About Universe Pharmaceuticals Inc
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong … Read more